Comments on reasons for third-party review pilot's unpopularity sought by FDA in letter to industry.
This article was originally published in The Gray Sheet
Executive Summary
FDA SEEKING COMMENTS ON THIRD-PARTY REVIEW PILOT "LOW UTILIZATION" through a letter on the pilot sent to third parties and device trade groups during the week of Nov. 18. Calling for comments by Dec. 15, the agency asks respondents to discuss "factors that may account for the industry's low utilization of the pilot program to date."
You may also be interested in...
Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
Hair Supplement Linked To Cases Of Severe Hepatitis In France
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: